Skip to main content
Clinical Trials/NCT03767491
NCT03767491
Withdrawn
N/A

Smartphone Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder: A Randomized, Waitlist-control Trial

Massachusetts General Hospital1 site in 1 countryJuly 1, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Obsessive-Compulsive Disorder
Sponsor
Massachusetts General Hospital
Locations
1
Primary Endpoint
Difference in OCD severity (Y-BOCS) at the end of treatment/waitlist period.
Status
Withdrawn
Last Updated
3 years ago

Overview

Brief Summary

The investigators are testing the efficacy of Smartphone-delivered cognitive behavioral therapy (CBT) treatment for obsessive compulsive disorder (OCD). The investigators hypothesize that participants receiving app-CBT will have greater improvement in Y-BOCS scores than those in the waitlist condition at treatment endpoint (week 12).

Detailed Description

The primary aims of this study are to test the efficacy of a Smartphone-based CBT treatment for adults with OCD recruited nationally. Eligible subjects (N=58) will be randomly assigned to 12 weeks of Smartphone-delivered CBT for OCD either immediately, or after a 12-week long waiting period (50-50 chance). The investigators hypothesize that Smartphone-delivered CBT for OCD will be feasible and acceptable to individuals with OCD, and that it will lead to greater reductions in OCD symptom severity compared to the passage of time (waitlist control).

Registry
clinicaltrials.gov
Start Date
July 1, 2019
End Date
June 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sabine Wilhelm, PhD

Chief of Psychology

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • at least 18 years of age
  • current diagnosis of primary DSM-5 OCD, based on MINI
  • currently living in the United States

Exclusion Criteria

  • Psychotropic medication changes within 2 months prior to enrollment (Participants taking psychotropic medication must have been on a stable dose for at least 2 months prior to enrollment and not change medication during study period)
  • Past participation in ≥ 4 sessions of CBT for OCD
  • Current severe substance use disorder
  • Lifetime bipolar disorder or psychosis
  • Acute, active suicidal ideation as indicated by clinical judgment and/or a score ≥ 2 on the suicidal ideation subscale of the C-SSRS
  • Current severe comorbid major depression, as indicated by clinical judgment and/or a QIDS-SR total score ≥ 21
  • Concurrent psychological treatment
  • Does not own a supported mobile Smartphone with a data plan
  • Lack of technology literacy that would interfere with ability to engage with smartphone treatment

Outcomes

Primary Outcomes

Difference in OCD severity (Y-BOCS) at the end of treatment/waitlist period.

Time Frame: Endpoint (week 12)

The Yale-Brown Obsessive Compulsive Scale (Y-BOCS) is the gold-standard, semi-structured clinician-administered assessment of OCD severity. It contains 10 items ranging from 0 to 4, which are summed to generate a total score (range = 0-40). Higher scores indicate more severe OCD symptoms. The Y-BOCS will be used to assess change in OCD symptoms from baseline to endpoint.

Secondary Outcomes

  • Difference in functional impairment at the end of treatment/waitlist period(Endpoint (week 12))
  • Difference in depression at the end of treatment/waitlist period(Endpoint (week 12))
  • Difference in quality of life at the end of treatment/waitlist period(Endpoint (week 12))

Study Sites (1)

Loading locations...

Similar Trials